Clinical Trials
12 trialsNCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT02810873 2025-05-04
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
Thomas Jefferson University
Phase NA Terminated
NCT02317783 2024-11-20
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
University of Utah
Phase 2 Terminated
NCT01931709 2023-11-18
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
University of Washington
Phase NA Terminated
NCT02149173 2021-06-30
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
University of Washington
Phase NA Terminated
NCT00602043 2020-02-19
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02455453 2020-01-14
Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Washington University School of Medicine
Phase 2 Completed
NCT01720602 2020-01-07
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase NA Completed
NCT01806675 2019-10-03
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Phase 1/2 Completed
NCT02599194 2019-01-03
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
Phase 2 Completed
NCT01222416 2017-07-02
PET/CT Evaluation of Treatment Response in Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Terminated